Mechanism of fas signaling regulation by human herpesvirus 8 K1 oncoprotein

Journal of the National Cancer Institute

Volumn 101, Issue 6, 2009, Pages 399-411

  Berkova, Zuzana ^a   Wang, Shu ^a   Wise, Jillian F ^a   Maeng, Hoyoung ^a,b   Ji, Yuan ^a   Samaniego, Felipe ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b National Health Insurance Corporation   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; FAS ANTIBODY; FAS ANTIGEN; FAS LIGAND; IMMUNOGLOBULIN; ONCOPROTEIN; ONCOPROTEIN K1; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL STRAIN HEK293; CONTROLLED STUDY; DELETION MUTANT; ENZYME DEGRADATION; EXPRESSION VECTOR; FEMALE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN HERPESVIRUS 8; LYMPHOMA CELL; MOUSE; NONHUMAN; PLASMID; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; SURVIVAL; VIRUS CELL INTERACTION; VIRUS ONCOGENE; WILD TYPE;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; FAS-ASSOCIATED DEATH DOMAIN PROTEIN; FLOW CYTOMETRY; GENE DELETION; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; IN SITU NICK-END LABELING; KIDNEY; LIVER; LYMPH NODES; LYMPHOMA; MICE; MUTATION; PLASMIDS; SIGNAL TRANSDUCTION; TRANSFECTION; VIRAL PROTEINS;

EID: 64949089835     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djn516     Document Type: Article

References (43)

1. Chang Y, Cesarman E, Pessin MS, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science. 1994; 266(5192):1865-1869.
2. Schulz TF. Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8): epidemiology and pathogenesis. J Antimicrob Chemother. 2000;45(suppl T3): 15-27.
3. Cesarman E, Knowles DM. The role of Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8) in lymphoproliferative diseases. Semin Cancer Biol. 1999;9(3):165-174.
4. Prakash O, Tang ZY, Peng X, et al. Tumorigenesis and aberrant signaling in transgenic mice expressing the human herpesvirus-8 K1 gene. J Natl Cancer Inst. 2002;94(12):926-935.
5. Lee BS, Paulose-Murphy M, Chung YH, Connlole M, Zeichner S, Jung JU. Suppression of tetradecanoyl phorbol acetate-induced lytic reactivation of Kaposi's sarcoma-associated herpesvirus by K1 signal transduction. J Virol. 2002;76(23):12185-12199.
6. Samaniego F, Pati S, Karp J, Prakash O, Bose D. Human herpesvirus 8 K1-associated nuclear factor-kappa B-dependent promoter activity: role in Kaposi's sarcoma inflammation? J Natl Cancer Inst Monogr. 2000; 2000(28):15-23.
7. Paulose-Murphy M, Ha N-K, Xiang C, et al. Transcription program of human herpesvirus 8 (Kaposi's sarcoma-associated herpesvirus). J Virol. 2001;75(10):4843-4853.
8. Wang L, Dittmer DP, Tomlinson CC, Fakhari FD, Damania B. Immortalization of primary endothelial cells by the K1 protein of Kaposi's sarcoma-associated herpesvirus. Cancer Res. 2006;66(7): 3658-3666.
9. Prakash O, Swamy OR, Peng X, et al. Activation of Src kinase Lyn by the Kaposi sarcoma-associated herpesvirus K1 protein: implications for lym-phomagenesis. Blood. 2005;105(10):3987-3994.
10. Lee BS, Lee SH, Feng P, Chang H, Cho NH, Jung JU. Characterization of the Kaposi's sarcoma-associated herpesvirus K1 signalosome. J Virol. 2005;79(19):12173-12184.
11. Lee H, Guo J, Li M, et al. Identification of an immunoreceptor tyrosine-based activation motif of K1 transforming protein of Kaposi's sarcoma-associated herpesvirus. Mol Cell Biol. 1998;18(9):5219-5228.
12. Lagunoff M, Majeti R, Weiss A, Ganem D. Deregulated signal transduction by the K1 gene product of Kaposi's sarcoma-associated herpesvirus. Proc Natl Acad Sci USA. 1999;96(10):5704-5709.
13. Wang S, Wang S, Maeng H, et al. K1 protein of human herpesvirus 8 suppresses lymphoma cell Fas-mediated apoptosis. Blood. 2007;109(5): 2174-2182.
14. Liu F, Song Y, Liu D. Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA Gene Ther. 1999;6(7):1258-1266.
15. Zender L, Hutker S, Liedtke C, et al. Caspase 8 small interfering RNA prevents acute liver failure in mice. Proc Natl Acad Sci USA. 2003; 100(13):7797-7802.
16. Poole LJ, Zong JC, Ciufo DM, et al. Comparison of genetic variability at multiple loci across the genomes of the major subtypes of Kaposi's sarcoma-associated herpesvirus reveals evidence for recombination and for two distinct types of open reading frame K15 alleles at the right-hand end. J Virol. 1999;73(8):6646-6660.
17. Lantner F, Starlets D, Gore Y, et al. CD74 induces TAp63 expression leading to B cell survival. Blood. 2007;110(13):4303-4311.
18. Lee BS, Connole M, Tang Z, Harris NL, Jung JU. Structural analysis of the Kaposi's sarcoma-associated herpesvirus K1 protein. J Virol. 2003; 77(14):8072-8086.
19. Siegel RM, Frederiksen JK, Zacharias DA, et al. Fas preassociation required for apoptosis signaling and dominant inhibition by pathogenic mutations. Science. 2000;288(5475):2354-2357.
20. Schneider P, Holler N, Bodmer JL, et al. Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. J Exp Med. 1998; 187(8):1205-1213.
21. Connolly K, Cho YH, Duan R, et al. In vivo inhibition of Fas ligand-mediated killing by TR6, a Fas ligand decoy receptor. J Pharmacol Exp Ther. 2001;298(1):25-33.
22. Samaniego F, Bryant JL, Liu N, et al. Induction of programmed cell death in Kaposi's sarcoma cells by preparations of human chorionic gonadotro-pin. J Natl Cancer Inst. 1999;91(2):135-143.
23. Wang X, De Frances MC, Dai Y, et al. A mechanism of cell survival: sequestration of Fas by the HGF receptor Met. Mol Cell. 2002;9(2): 411-121.
24. Schuchmann M, Varfolomeev EE, Hermann F, et al. Dominant negative MORT1/FADD rescues mice from CD95 and TNF-induced liver failure. Hepatology. 2003;37(1):129-135.
25. Larregina AT, Morelli AE, Dewey RA, Castro MG, Fontana A, Lowenstein PR. Fas L induces Fas/Apo1-mediated apoptosis in human embryonic kidney 293 cells routinely used to generate E1-deleted adenoviral vectors. Gene Ther. 1998;5(4):563-568.
26. Fouchard N, Lacoste V, Couppie P, et al. Detection and genetic polymorphism of human herpes virus type 8 in endemic or epidemic Kaposi's sarcoma from West and Central Africa, and South America. Int J Cancer. 2000;85(2):166-170.
27. Abe J, Okuda M, Huang Q, Yoshizumi M, Berk BC. Reactive oxygen species activate p90 ribosomal S6 kinase via Fyn and Ras. J Biol Chem. 2000;275(3):1739-1748.
28. Schneider P, Bodmer JL, Holler N, et al. Characterization of Fas (Apo-1, CD95)-Fas ligand interaction. J Biol Chem. 1997;272(30):18827-18833.
29. Fadeel B, Lindberg J, Achour A, Chiodi F. A three-dimensional model of the Fas/APO-1 molecule: cross-reactivity of anti-Fas antibodies explained by structural mimicry of antigenic sites. Int Immunol. 1998;10(2): 131-140.
30. Choi J, Means RE, Damania B, Jung JU. Molecular piracy of Kaposi's sarcoma associated herpesvirus. Cytokine Growth Factor Rev. 2001;12(2-3): 245-257.
31. McGeoch DJ. Molecular evolution of the gamma-Herpesvirinae. Philos Trans R Soc Lond B Biol Sci. 2001;356(1408):421-435.
32. Lee BS, Alvarez X, Ishido S, Lackner AA, Jung JU. Inhibition of intracellular transport of B cell antigen receptor complexes by Kaposi's sarcoma-associated herpesvirus K1. J Exp Med. 2000;192(1):11-21.
33. Stel AJ, Ten Cate B, Jacobs S, et al. Fas receptor clustering and involvement of the death receptor pathway in rituximab-mediated apoptosis with concomitant sensitization of lymphoma B cells to Fas-induced apoptosis. J Immunol. 2007;178(4):2287-2295.
34. Plumas J, Jacob MC, Chaperot L, Molens JP, Sotto JJ, Bensa JC. Tumor B cells from non-Hodgkin's lymphoma are resistant to CD95 (Fas/Apo-1)-mediated apoptosis. Blood. 1998;91(8):2875-2885.
35. de Totero D, Montera M, Rosso O, et al. Resistance to CD95-mediated apoptosis of CD40-activated chronic lymphocytic leukemia B cells is not related to lack of DISC molecules expression. Hematol J. 2004;5(2): 152-160.
36. Vega MI, Huerta-Yepez S, Jazirehi AR, Garban H, Bonavida B. Rituximab (chimeric anti-CD20) sensitizes B-NHL cell lines to Fas-induced apoptosis. Oncogene. 2005;24(55):8114-8127.
37. Bonavida B. Rituximab-induced inhibition of antiapoptotic cell survival pathways: implications in chemo/immunoresistance, rituximab unrespon-siveness, prognostic and novel therapeutic interventions. Oncogene. 2007;26(25):3629-3636.
38. Lajmanovich A, Irisarri M, Molens JP, et al. Impairment of death-inducing signalling complex formation in CD95-resistant human primary lymphoma B cells. Br J Haematol. 2004;124(6):746-753.
39. Mielgo A, van Driel M, Bloem A, Landmann L, Gunthert U. A novel antiapoptotic mechanism based on interference of Fas signaling by CD44 variant isoforms. Cell Death Differ. 2006;13(3):465-477.
40. Corso S, Comoglio PM, Giordano S. Cancer therapy: can the challenge be MET? Trends Mol Med. 2005;11(6):284-292.
41. Smyth LA, Brady HJ. cMet and Fas receptor interaction inhibits death-inducing signaling complex formation in endothelial cells. Hypertension. 2005;46(1):100-106.
42. Gherardi E, Youles ME, Miguel RN, et al. Functional map and domain structure of MET, the product of the c-met protooncogene and receptor for hepatocyte growth factor/scatter factor. Proc Natl Acad Sci USA. 2003;100(21):12039-12044.
43. Hitoshi Y, Lorens J, Kitada SI, et al. Toso, a cell surface, specific regulator of Fas-induced apoptosis in T cells. Immunity. 1998;8(4):461-471.